APA (7th ed.) Citation

Houlind, M. B., Hansen, L., Iversen, E., Rasmussen, H. B., Larsen, J. B., Jørgensen, S., . . . Westergaard, N. (2024). Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification. Basic & Clinical Pharmacology & Toxicology, 134(5), 756. https://doi.org/10.1111/bcpt.13990

Chicago Style (17th ed.) Citation

Houlind, Morten Baltzer, et al. "Pharmacogenetic Testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement Between Publicly Funded Genotyping Tests and the Subsequent Phenotype Classification." Basic & Clinical Pharmacology & Toxicology 134, no. 5 (2024): 756. https://doi.org/10.1111/bcpt.13990.

MLA (9th ed.) Citation

Houlind, Morten Baltzer, et al. "Pharmacogenetic Testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement Between Publicly Funded Genotyping Tests and the Subsequent Phenotype Classification." Basic & Clinical Pharmacology & Toxicology, vol. 134, no. 5, 2024, p. 756, https://doi.org/10.1111/bcpt.13990.